AstraZeneca Pharma India LimitedASTRAZENCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 14 quarters of data

₹5,970.50

MCap ₹14,926 Cr · P/E 88.1

AstraZeneca Pharma India Limited — Stock analysis & AI research AstraZeneca Pharma India Limited — Seasonality — best & worst months AstraZeneca Pharma India Limited — Technical indicators & charts AstraZeneca Pharma India Limited — Technical setup — score, trend, support & resistance AstraZeneca Pharma India Limited — Live exchange announcements

📋 High ROCE Stocks 📋 High Interest Coverage Stocks 📋 High Sales Growth Stocks 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 📋 Small Cap Stocks List 📈 MACD Bullish Crossover 📈 Multi-Timeframe Bearish Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹683 Cr

Sales · Jun 2026

+29.7% YoY

₹49 Cr

Operating Profit · Jun 2026

-39.7% YoY

7.2%

OPM % · Jun 2026

-53.2% YoY

₹38 Cr

Net Profit · Jun 2026

-32.1% YoY

₹15.17

EPS · Jun 2026

-32.1% YoY

📝 AstraZeneca Pharma India Limited — results explained

Quarter ended June 2026 (Q1 FY27)

AstraZeneca Pharma India Limited reported revenue of ₹683 crore for the quarter ended June 2026 (Q1 FY27), up 29.7% from ₹526 crore in the same quarter last year, and up 17.9% sequentially over the March 2026 quarter.

Net profit fell 32.1% year-on-year to ₹38 crore, from ₹56 crore. Earnings per share (EPS) came in at ₹15.17.

Operating profit stood at ₹49 crore — an operating margin (OPM) of 7.2%, compared with 15.4% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, AstraZeneca Pharma India Limited posted revenue of ₹2,276 crore, a growth of 32.7% over FY25, with a net profit of ₹187 crore (up 62.1% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹2,432 crore with a net profit of ₹170 crore.

Valuation snapshot

At the current price of ₹5,970.50, ASTRAZEN has a market capitalisation of ₹14,926 crore and a trailing P/E of about 88.1.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 25th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 75.00%, foreign institutional investors (FIIs) 2.68%, domestic institutional investors (DIIs) 6.08%, public shareholders 16.24% of AstraZeneca Pharma India Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹14,926 Cr

Current Price ?

₹5,970.5

P/E ?

88.05above ind

Industry P/E ?

35.00

P/B ?

17.10

P/S ?

6.14

P/FCF ?

-829.24

Enterprise Value ?

₹15,037 Cr

EV/EBITDA ?

65.44

PEG ?

5.87

Earnings Yield ?

1.4%

Dividend Yield ?

0.54%

Profitability & Returns

Sales (TTM) ?

₹2,432 Cr

OPM ?

9.4%

Profit after tax (TTM) ?

₹170 Cr

EPS (TTM) ?

₹67.81

ROCE ?

29.0%

ROE ?

19.4%

ROA ?

8.5%

Growth

Sales — latest qtr ?

₹683 Cr

PAT — latest qtr ?

₹38 Cr

YoY qtr sales growth ?

29.7%

YoY qtr profit growth ?

-32.1%

Sales growth (3y) ?

31%

Sales growth (5y) ?

23%

Profit growth (3y) ?

15%

Profit growth (5y) ?

16%

Financial Health

Debt ?

₹111 Cr

Debt to Equity ?

0.13

Interest Coverage ?

48.6

Current Ratio ?

N/A

Ownership

Promoter holding ?

75.00%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

-25.6%

Return 6 months ?

-29.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	YoY %	QoQ %
Sales	285	295	311	306	383	388	408	440	480	526	559	612	579	683	+29.7%	+17.9%
Operating Profit	60	67	53	15	49	38	53	77	86	81	75	45	61	49	-39.7%	-19.8%
Other Income	-32	8	8	10	9	8	8	-26	10	11	1	5	5	9	-17.9%	+84.6%
Interest	0	0	1	1	-0	0	0	0	1	1	1	1	2	2	+170.8%	-2.5%
Depreciation	4	4	4	4	4	4	9	9	18	17	3	4	6	5	-68.4%	-12.8%
Profit Before Tax	23	71	73	20	54	-15	51	42	78	75	73	47	58	51	-32.1%	-12.5%
Net Profit	17	54	52	16	39	-12	38	31	58	56	54	33	45	38	-32.1%	-15.7%
EPS	6.91	21.54	20.95	6.32	15.79	-4.72	15.37	12.34	23.30	22.33	21.69	13.04	17.95	15.17	-32.1%	-15.5%
OPM %	21.1%	22.8%	17.0%	4.9%	12.9%	9.8%	12.9%	17.5%	17.9%	15.4%	13.4%	7.3%	10.5%	7.2%	-53.2%	-31.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric	FY25	FY26	TTM	YoY %
Sales	₹1,716 Cr	₹2,276 Cr	₹2,432 Cr	+32.7%
Operating Profit	₹254 Cr	₹262 Cr	₹230 Cr	+3.3%
OPM %	14.78%	11.51%	9.45%	-22.1%
NPM %	6.74%	8.24%	6.97%	+22.3%
Other Income	₹0 Cr	₹22 Cr	₹20 Cr	+4374.0%
Depreciation	₹40 Cr	₹29 Cr	₹18 Cr	-26.9%
Interest	₹1 Cr	₹5 Cr	₹6 Cr	+229.7%
EBIT	₹213 Cr	₹233 Cr	₹212 Cr	+9.0%
PBT	₹156 Cr	₹252 Cr	₹228 Cr	+61.8%
Tax	₹9 Cr	₹33 Cr	₹27 Cr	+255.6%
Net Profit	₹116 Cr	₹187 Cr	₹170 Cr	+62.1%
EPS	₹46.29	₹75.01	₹67.85	+62.0%
Material Cost	₹615 Cr	₹1,124 Cr	₹1,002 Cr	+82.7%
Employee Cost	₹129 Cr	₹158 Cr	₹173 Cr	+22.7%
Extraordinary Items	₹-58 Cr	₹1 Cr	₹1 Cr	+101.9%

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	5	5	5	5	+0.0%
Reserves	584	707	765	868	+13.5%
Borrowings	7	5	36	111	+208.3%
Other Liabilities	389	362	712	1,006	+41.3%
Total Liabilities	985	1,078	1,518	1,989	+31.0%
Fixed Assets	69	67	64	117	+82.8%
CWIP	1	0	0	0	—
Investments	0	0	0	0	—
Other Assets	915	1,011	1,454	1,872	+28.7%
Total Assets	985	1,078	1,518	1,989	+31.0%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	58	28	65	-15	-123.1%
Cash from Investing Activity	18	22	31	19	-38.7%
Cash from Financing Activity	-24	-44	-66	-92	-39.4%
Net Cash Flow	52	5	31	-88	-383.9%
Free Cash Flow	53	18	64	-18	-128.1%
CFO/OP	60%	46%	51%	26%	-49.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	39	43	39	34	-12.8%
Inventory Days	193	140	208	272	+30.8%
Days Payable	231	121	173	207	+19.7%
Cash Conversion Cycle	1	62	74	99	+33.8%
Working Capital Days	-18	20	22	50	+127.3%
ROCE %	31%	31%	33%	29%	-12.1%

👥 Shareholding (latest 5 periods)

Metric	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	% Chg
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	+0.0%
FIIs	3.03%	2.74%	2.71%	2.78%	2.68%	-3.6%
DIIs	4.55%	5.26%	5.55%	5.79%	6.08%	+5.0%
Public	17.41%	17.00%	16.73%	16.42%	16.24%	-1.1%
No. of Shareholders	34,378	32,914	31,551	29,007	29,338	+1.1%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	SUNPHARMA Sun Pharmaceutical	₹1,840.00	441,478	36.5	59,911	12,104	29.8%	20.2%	11.2%	5.1%	10.5%	27.0%
2	DIVISLAB Divi's Laboratories	₹9,235.00	245,160	83.8	11,230	2,925	35.3%	26.0%	12.8%	16.7%	27.8%	65.5%
3	TORNTPHARM Torrent Pharmaceuticals	₹4,931.00	187,559	87.1	15,723	2,156	33.0%	13.7%	21.4%	11.9%	54.8%	3.3%
4	ZYDUSLIFE Zydus Lifesciences	₹1,162.20	115,930	23.2	27,148	5,070	31.2%	18.7%	16.8%	12.0%	16.2%	14.5%
5	CIPLA Cipla	₹1,366.00	110,353	32.7	28,324	3,356	18.7%	11.8%	2.2%	-26.7%	2.3%	-39.2%
6	LAURUSLABS Laurus Labs	₹1,969.00	106,387	97.2	7,270	1,090	28.0%	15.0%	22.7%	147.9%	29.1%	123.9%
7	DRREDDY Dr. Reddy's	₹1,165.50	97,085	29.3	28,704	3,273	15.3%	11.4%	-10.4%	-25.8%	-5.6%	-69.2%
8	AUROPHARMA Aurobindo Pharma	₹1,679.80	96,652	26.2	34,935	3,711	20.3%	10.6%	6.1%	0.6%	16.3%	25.2%
9	LUPIN Lupin	₹2,095.00	95,797	17.9	27,958	5,356	31.5%	19.2%	23.1%	62.0%	31.9%	87.8%
10	MANKIND Mankind Pharma	₹2,280.00	94,174	46.1	14,738	2,067	26.0%	14.0%	16.3%	-3.7%	12.9%	29.1%
11	GLENMARK Glenmark Pharmaceuticals	₹2,419.20	68,276	38.0	17,737	1,797	27.0%	10.1%	-61.2%	-67.4%	23.1%	927.9%
12	ALKEM Alkem Laboratories	₹5,243.50	62,694	29.1	15,081	2,187	20.1%	14.5%	13.5%	7.6%	10.9%	-21.6%
13	ABBOTINDIA Abbott India	₹25,860.00	54,951	34.0	7,005	1,615	28.1%	23.1%	8.1%	9.7%	4.4%	17.2%
14	IPCALAB Ipca Laboratories	₹1,964.20	49,833	38.0	10,125	1,379	22.0%	13.6%	7.9%	55.0%	20.8%	82.2%
15	GLAND Gland Pharma	₹2,935.90	48,433	47.1	6,431	1,028	25.3%	16.0%	-64.7%	-48.4%	22.3%	96.7%
16	AJANTPHARM Ajanta Pharma	₹3,398.90	42,472	37.4	5,777	1,135	25.4%	19.7%	17.3%	14.8%	24.8%	30.9%
17	JBCHEPHARM J. B.	₹2,416.10	38,793	53.4	4,148	709	26.7%	17.1%	5.9%	7.5%	-4.8%	-30.7%
18	EMCURE EMCURE PHARMACEUTICALS	₹1,975.10	37,470	37.0	9,684	1,019	20.4%	10.5%	16.6%	33.1%	22.8%	36.0%
19	WOCKPHARMA Wockhardt	₹2,021.50	32,848	92.5	3,133	353	19.9%	11.3%	-2.3%	342.1%	25.9%	199.1%
20	NEULANDLAB Neuland Laboratories	₹23,455.00	30,093	82.7	2,023	365	28.4%	18.0%	37.0%	40.2%	136.3%	666.0%
21	PPLPHARMA Piramal Pharma	₹211.50	28,024	113.5	9,206	247	11.0%	2.7%	-3.1%	-37.9%	17.4%	-161.3%
22	GRANULES Granules India	₹885.60	21,945	32.8	5,633	663	22.7%	11.8%	19.7%	18.8%	22.0%	59.3%
23	CAPLIPOINT Caplin Point	₹2,752.60	20,923	31.4	2,287	678	34.8%	29.7%	12.9%	20.2%	19.6%	18.8%
24	ERIS Eris Lifesciences	₹1,358.00	18,820	29.0	3,230	666	35.2%	20.6%	8.2%	72.6%	13.0%	14.6%
25	ASTRAZEN AstraZeneca Pharma	₹6,755.00	16,888	99.6	2,432	170	9.4%	7.0%	32.7%	62.1%	29.7%	-32.1%

❓ Frequently asked questions

What was AstraZeneca Pharma India Limited's revenue in Q1 FY27?

What was AstraZeneca Pharma India Limited's net profit in Q1 FY27?